<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930991</url>
  </required_header>
  <id_info>
    <org_study_id>OU202005AJ-OmeprazolePanc</org_study_id>
    <nct_id>NCT04930991</nct_id>
  </id_info>
  <brief_title>High Dose Omeprazole in Patients With Pancreatic Cancer</brief_title>
  <official_title>A Phase 0 Study of High Dose Omeprazole in Patients With Pancreatic Cancer Planning to Undergo Surgical Therapy for Evaluating Changes of Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of high dose omeprazole and see what effects&#xD;
      that it has on patients with exocrine pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During this study patients will receive treatment of omeprazole at the dose depending on&#xD;
      group enrollment&#xD;
&#xD;
        -  Group A will receive omeprazole 80 mg, twice a day for 14 days unless unacceptable&#xD;
           toxicity&#xD;
&#xD;
        -  Group B, will receive omeprazole 20 mg, once a day for 14 days&#xD;
&#xD;
      Patients will receive treatment for 2~3 weeks during the study, and 2 months of follow up.&#xD;
&#xD;
      Total accrual is anticipated to take 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of subjects receiving study treatment without adverse events that would significantly delay the surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency and severity of treatment related adverse events per CTCAE v5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>v-ATPase LC3-I and LC3-II expression</measure>
    <time_frame>2 years</time_frame>
    <description>v-ATPase LC3-I and LC3-II expression on pancreatic tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>2 years</time_frame>
    <description>pH of tumor tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of biomarker changes with potential cancer cell apoptosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Exocrine Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omeprazole, 80 mg, PO, BID for 2 weeks prior to surgical therapy of pancreatectomy. All 30 subjects in Arm A to be enrolled prior to Arm B cohort enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Normal Dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Omeprazole, 20 mg, PO, QD for 2 weeks prior to surgical therapy of pancreatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Treatment will consist of Omeprazole 2 weeks prior to surgical therapy of pancreatectomy.</description>
    <arm_group_label>Arm A (High Dose)</arm_group_label>
    <arm_group_label>Arm B (Normal Dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed exocrine pancreatic cancer with pathology confirmed as adenocarcinoma&#xD;
&#xD;
          -  Patient is a candidate for surgical resection of pancreatic cancer&#xD;
&#xD;
          -  â‰¥ 18 years old at the time of informed consent&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Patients with or without neoadjuvant chemotherapy will be eligible&#xD;
&#xD;
          -  Ability to provide written informed consent and HIPAA authorization&#xD;
&#xD;
          -  Women of childbearing potential definition must have a negative pregnancy test within&#xD;
             14 days of registration. All women (regardless of sexual orientation, having undergone&#xD;
             a tubal ligation, or remaining celibate by choice) are considered to have childbearing&#xD;
             potential unless they meet one of the following criteria:&#xD;
&#xD;
          -  Prior hysterectomy or bilateral oophorectomy;&#xD;
&#xD;
          -  Has not had menses at any time in the preceding 24 consecutive months&#xD;
&#xD;
          -  Adequate organ function for surgical therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or&#xD;
             any other type of malignancies&#xD;
&#xD;
          -  Positive pregnancy test, pregnant, or breastfeeding&#xD;
&#xD;
          -  Known hypersensitivity to any component of the formulation or substituted&#xD;
             benzimidazoles&#xD;
&#xD;
          -  Any other clinically significant laboratory abnormality that would compromise patient&#xD;
             safety or the outcome of the study&#xD;
&#xD;
          -  Any clinically significant and/or uncontrolled cardiac-related abnormality that would&#xD;
             compromise patient safety or the outcome of the study&#xD;
&#xD;
          -  Medical condition that might affect the absorption of study medications in the opinion&#xD;
             of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SCC IIT Office</last_name>
    <phone>405-271-8777</phone>
    <email>SCC-IIT-Office@ouhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid Block</last_name>
    <phone>405-271-8777</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCC IIT Office</last_name>
      <phone>405-271-8777</phone>
      <email>SCC-IIT-Office@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>omeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

